Terms: = Ovarian cancer AND IKZF1, LyF-1, 10320, ENSG00000185811, Q13422, Hs_54452, hIk-1, ZNFN1A1, IKAROS
5 results:
1. Design and Development of IKZF2 and CK1α Dual Degraders.
Miyamoto DK; Curnutt NM; Park SM; Stavropoulos A; Kharas MG; Woo CM
J Med Chem; 2023 Dec; 66(24):16953-16979. PubMed ID: 38085607
[TBL] [Abstract] [Full Text] [Related]
2. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Nteliopoulos G; Bazeos A; Claudiani S; Gerrard G; Curry E; Szydlo R; Alikian M; Foong HE; Nikolakopoulou Z; Loaiza S; Khorashad JS; Milojkovic D; Perrotti D; Gale RP; Foroni L; Apperley JF
Haematologica; 2019 Dec; 104(12):2400-2409. PubMed ID: 31073075
[TBL] [Abstract] [Full Text] [Related]
3. ikaros inhibits proliferation and, through upregulation of Slug, increases metastatic ability of ovarian serous adenocarcinoma cells.
He LC; Gao FH; Xu HZ; Zhao S; Ma CM; Li J; Zhang S; Wu YL
Oncol Rep; 2012 Oct; 28(4):1399-405. PubMed ID: 22859015
[TBL] [Abstract] [Full Text] [Related]
4. Integrative genomic analyses on ikaros and its expression related to solid cancer prognosis.
Yang L; Luo Y; Wei J
Oncol Rep; 2010 Aug; 24(2):571-7. PubMed ID: 20596648
[TBL] [Abstract] [Full Text] [Related]
5. A heterodimeric nuclear protein complex binds two palindromic sequences in the proximal enhancer of the human erbB-2 gene.
Chen Y; Gill GN
J Biol Chem; 1996 Mar; 271(9):5183-8. PubMed ID: 8617800
[TBL] [Abstract] [Full Text] [Related]
